Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
$7.71
+2.8%
$8.03
$6.10
$28.67
$534.54M1.41395,256 shs72,401 shs
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
$0.64
+2.7%
$4.97
$0.24
$1.49
$9.50M2.82127,174 shs79,747 shs
Kamada Ltd. stock logo
KMDA
Kamada
$7.80
+1.4%
$7.08
$5.08
$9.16
$446.57M0.9695,788 shs14,310 shs
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$12.17
+4.9%
$8.34
$6.53
$30.60
$106.09M2.75132,297 shs60,866 shs
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$10.41
+4.9%
$8.26
$5.79
$11.78
$1.65B1.431.42 million shs731,303 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
+4.60%+6.69%-12.28%+9.01%-62.93%
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
-3.98%-3.28%-10.13%-54.42%-86.50%
Kamada Ltd. stock logo
KMDA
Kamada
-0.13%-0.77%+12.41%+27.69%+34.85%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
+6.91%+8.41%+40.95%+8.21%-40.40%
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
+3.23%+9.01%+9.98%+45.03%+48.95%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
3.8182 of 5 stars
4.44.00.00.02.22.50.6
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Kamada Ltd. stock logo
KMDA
Kamada
4.044 of 5 stars
3.33.00.00.02.01.73.8
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
3.5484 of 5 stars
2.92.00.04.62.80.80.0
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
3.9377 of 5 stars
3.51.00.04.12.92.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
2.70
Moderate Buy$25.00224.21% Upside
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
0.00
N/AN/AN/A
Kamada Ltd. stock logo
KMDA
Kamada
2.67
Moderate Buy$13.0066.58% Upside
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
1.75
Reduce$73.67505.31% Upside
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
3.00
Buy$17.3366.51% Upside

Current Analyst Ratings Breakdown

Latest OCUL, BCYC, GEMP, KMDA, and MCRB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/29/2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00
5/15/2025
Kamada Ltd. stock logo
KMDA
Kamada
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
5/8/2025
Kamada Ltd. stock logo
KMDA
Kamada
Sidoti
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
5/8/2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$1.25 ➝ $6.00
5/6/2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $14.00
5/5/2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $17.00
5/2/2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$35.00 ➝ $32.00
5/2/2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$17.00 ➝ $14.00
5/2/2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$26.00 ➝ $22.00
5/2/2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
5/1/2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$40.00 ➝ $15.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
$35.28M15.14N/AN/A$11.48 per share0.67
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/AN/AN/AN/A$0.54 per shareN/A
Kamada Ltd. stock logo
KMDA
Kamada
$160.95M2.79$0.50 per share15.68$4.51 per share1.73
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/AN/AN/AN/A$1.61 per shareN/A
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$63.72M26.03N/AN/A$2.01 per share5.18
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
-$169.03M-$3.14N/AN/AN/A-790.07%-25.54%-21.23%8/5/2025 (Estimated)
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
-$23.64MN/A0.00N/AN/A-419.70%-173.05%N/A
Kamada Ltd. stock logo
KMDA
Kamada
$14.46M$0.2926.7824.390.939.60%6.31%4.43%8/13/2025 (Estimated)
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$140K-$4.60N/AN/AN/AN/A-41,084.76%-55.87%8/12/2025 (Estimated)
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
-$193.51M-$1.15N/AN/AN/A-323.09%-59.92%-41.98%8/6/2025 (Estimated)

Latest OCUL, BCYC, GEMP, KMDA, and MCRB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
-$0.35N/AN/AN/A$13.12 millionN/A
8/5/2025Q2 2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
-$0.95N/AN/AN/A$9.43 millionN/A
5/14/2025Q1 2025
Kamada Ltd. stock logo
KMDA
Kamada
$0.07$0.07N/A$0.07$154.06 million$44.02 million
5/7/2025Q1 2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-$0.67-$2.24-$1.57$3.75$10.00 millionN/A
5/1/2025Q1 2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
-$0.86-$0.88-$0.02-$0.88$8.67 million$9.98 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
N/AN/AN/AN/AN/A
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/AN/AN/AN/AN/A
Kamada Ltd. stock logo
KMDA
Kamada
N/AN/AN/AN/AN/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/AN/AN/AN/AN/A
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
N/A
14.86
14.86
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/A
0.67
0.67
Kamada Ltd. stock logo
KMDA
Kamada
N/A
3.30
1.93
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/A
2.11
2.11
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
0.26
10.22
10.14

Institutional Ownership

CompanyInstitutional Ownership
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
86.15%
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
17.53%
Kamada Ltd. stock logo
KMDA
Kamada
20.38%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
59.34%
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
59.21%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
24069.25 million63.37 millionOptionable
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
914.87 millionN/ANot Optionable
Kamada Ltd. stock logo
KMDA
Kamada
36057.51 million36.75 millionOptionable
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
3308.73 million8.32 millionOptionable
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
230159.30 million155.64 millionOptionable

Recent News About These Companies

Q&A: Justis P. Ehlers, MD, on the Phase 1 HELIOS NPDR trial

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bicycle Therapeutics stock logo

Bicycle Therapeutics NASDAQ:BCYC

$7.71 +0.21 (+2.81%)
As of 11:28 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Gemphire Therapeutics stock logo

Gemphire Therapeutics NASDAQ:GEMP

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.

Kamada stock logo

Kamada NASDAQ:KMDA

$7.80 +0.10 (+1.35%)
As of 11:25 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Seres Therapeutics stock logo

Seres Therapeutics NASDAQ:MCRB

$12.17 +0.57 (+4.91%)
As of 11:29 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Ocular Therapeutix stock logo

Ocular Therapeutix NASDAQ:OCUL

$10.41 +0.49 (+4.94%)
As of 11:29 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.